Doctors have been starting to use the newer drugs such as Xtandi (enzalutamide) and Zytiga (abiraterone) before docetaxel. This has moved chemotherapy further back in the sequence of treatment.   Now there is evidence for a role for earlier chemotherapy for some men.  By moving docetaxel from the castration-resistant stage, when men were not responding to testosterone-lowering agents, to the castration-sensitive state, when they were, the survival benefits were amplified.   The evidence come